• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Prepregnancy Diabetes: Does Better Glycemic Control Reduce the Risk for Adverse Events?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Prepregnancy diabetes is associated with morbidity and adverse pregnancy outcomes, especially if glycemic control is suboptimal
  • However, it is unclear if improving glycemic control from preconception to mid early pregnancy and midpregnancy can reduce adverse outcomes
  • Davidson et al. (JAMA Network Open, 2020) assessed whether improved glycemic control from preconception to the first half of pregnancy is associated with a lower risk of adverse outcomes

METHODS:

  • Population-based cohort study
  • Population
    • Births among women with prepregnancy diabetes
  • Exposures
    • Net decrease in HbA1c from preconception to early pregnancy and midpregnancy
  • Study design
    • HbA1C was measured (1) within 90 days preconception and (2) from conception through 21 weeks
    • Adjustments were made for maternal age at conception, preconception HbA1C and hemoglobin concentration, and gestational age at HbA1C measurement
  • Primary outcome
    • Congenital anomaly from birth to age 1 year
  • Secondary outcomes
    • Neonatal: Preterm birth <37 weeks, stillbirth or neonatal death  
    • Severe maternal morbidity (SMM) that is a composite of approximately 40 perinatal indicators or maternal death

RESULTS:

  • 3459 births
    • Mean maternal age 32.6 years
  • Overall, the mean HbA1c decreased from prepregnancy to early-to-midpregnancy
    • Preconception: 7.2%
    • Early to midpregnancy: 6.4%

Congenital Anomalies

  • Overall
    • Incidence: 14.4%
    • Adjusted relative risk (aRR) 0.94 (95% CI, 0.89 to 0.98) per 0.5% net decrease in HbA1c
  • Cardiac anomalies
    • aRR 1.09 (95% CI, 1.06-1.13) per 0.5% increase in preconception HbA1
  • Benefit of net decrease in HbA1C
    • 2.0% absolute net decrease in HbA1C: 12.0% absolute risk for congenital anomaly (95% CI, 14.0% to 17.4%)
    • 0% net decrease in HbA1C: 15.6% absolute risk for congenital anomaly (95% CI, 10.4% to 13.8%)
    • Benefit most apparent in women with preconception HbA1C ≥6.4%

Preterm Birth

  • Improved glycemic control was associated with a reduced risk for preterm birth
    • aRR 0.89 (95% CI, 0.86 to 0.91)
  • Preterm birth (<37 weeks)
    • aRR 1.08 (95% CI, 1.06-1.09) for each 0.5% higher preconception HbA1C  
  • Extreme preterm birth (<32 weeks)
    • aRR (1.09; 95% CI, 1.04-1.14) for each 0.5% higher preconception HbA1C
  • Perinatal mortality
    • aRR (1.16; 95% CI, 1.11-1.22) for each 0.5% higher preconception HbA1C

Maternal Outcomes

  • SMM or death from 21 weeks up to 42 days postpartum
    • Incidence: 5.5%
    • aRR 0.90 (95% CI, 0.84 to 0.96) for each 0.5% net decrease in HbA1C

CONCLUSION:

  • Women with prepregnancy diabetes who obtain better glycemic control between preconception and early-to-midpregnancy (prior to 21 weeks) may reduce their risk of adverse neonatal and maternal outcomes including preterm birth
  • The rate of SMM was higher than expected as was the probability of a congenital anomaly, suggesting the patients in this current study may have been especially predisposed to adverse events
  • The authors point out that with half of all pregnancies unplanned in Canada and the United States, improved periconception glucose control may be beneficial especially in women with preconception HbA1C above 6.4%   

Learn More – Primary Sources:

Association of Improved Periconception Hemoglobin A1c With Pregnancy Outcomes in Women With Diabetes

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Multiple Injections or Continuous Insulin Infusion for Type 1 Diabetes Mellitus in Pregnancy?
Can Software-Guided Insulin Dosing Improve Glucose Control During Labor?
CONCEPTT Study: Time for Continuous Glucose Monitoring for All Pregnant Women with Type 1 Diabetes?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site